Oops, looks like you need to register to access this feature.
Select “Keep Exploring” to look around Scholars in Medicine. You have full access to all videos and podcasts for a limited time. Registration is provided at no cost exclusively for healthcare providers.
Sign Up or Log In
SIM - Scholars in Medicine Logo
SIM - Scholars in Medicine Logo
Founding Sponsors
Register

Adalimumab-aaty 40mg/80mg SC

Brand and Other Names: Yuflyma
Mechanism of Action:
Adalimumab products bind specifically to TNF-alpha and block itsinteraction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab productsdo not bind or inactivate lymphotoxin (TNF-beta).TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. See package insert for complete information
Indications:

YUFLYMA is a tumor necrosis factor (TNF) blocker indicated for:
•Rheumatoid Arthritis (RA)
•Juvenile Idiopathic Arthritis (JIA)
•Psoriatic Arthritis (PsA)
•Ankylosing Spondylitis (AS)
•Crohn’s Disease (CD)
•Ulcerative Colitis (UC)
•Plaque Psoriasis (Ps)
•Hidradenitis Suppurativa (HS) See package insert for complete information

Route: Subcutaneous
Dose:

Injection:
• Single-dose prefilled auto-injector (YUFLYMA AI): 40 mg/0.4 mL
• Single-dose prefilled syringe with safety guard : 40 mg/0.4 mL 
• Single-dose prefilled syringe: 40 mg/0.4 mL

Adverse Reactions:
Most common adverse reactions (>10%) are: infections (e.g., upper respiratory, sinusitis), injection site reactions, headache, and rash.
Contraindication:
None
Warnings and Precautions:

• Serious infections: Do not start YUFLYMA during an active infection. If an infection develops, monitor carefully, and stop YUFLYMA if infection becomes serious.
• Invasive fungal infections: For patients who develop a systemic illness on YUFLYMA, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic.
• Malignancies: Incidence of malignancies was greater in adalimumab-treated patients than in controls.
• Anaphylaxis or serious hypersensitivity reactions may occur.
• Hepatitis B virus reactivation: Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop YUFLYMA and begin anti-viral therapy.
• Demyelinating disease: Exacerbation or new onset, may occur.
• Cytopenias, pancytopenia: Advise patients to seek immediate medical attention if symptoms develop, and consider stopping YUFLYMA.
• Heart failure: Worsening or new onset, may occur.
• Lupus-like syndrome: Stop YUFLYMA.

See package insert for full prescribing information.